• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Unicycive Therapeutics, Inc. - Common Stock (NQ:UNCY)

    4.770 -0.040 (-0.83%)
    Streaming Delayed Price Updated: 11:59 AM EDT, Oct 31, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Unicycive Therapeutics, Inc. - Common Stock

    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    12 Health Care Stocks Moving In Wednesday's Intraday Session
     
    Via Benzinga
    Dow Tumbles 150 Points; Crude Oil Falls Sharply
    U.S. stocks turned lower midway through trading, with the Dow Jones dropping around 150 points on Wednesday. 
    Via Benzinga
    Unicycive Shares Jump As Renazorb Achieves Primary Endpoint In Bioequivalence Study
     
    Via Benzinga
    Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom
    Expects to dose patients in first-in-human Phase 1 study with UNI-494 in first quarter 2023 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Therapeutics' Geographic Atrophy Candidate Shows Improved Contrast Vision In Animal Studies
     
    Via Benzinga
    Unicycive Inks Licensing Pact For Its Kidney Disease Candidate In China
     
    Via Benzinga
    Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)
    Via ACCESSWIRE
    Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive
    In the U.S., reimbursement of dialysis expenses by the Centers for Medicare & Medicaid Services (CMS) is done using a prospective payment system (PPS) which enables the payout of a predetermined amount... 
    Via Benzinga
    Unicycive to Participate in Upcoming Investor Conferences
    Highlights Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Announces Third Quarter Financial Results and Provides Business Update
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB™ (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Gainers 
    Via Benzinga
    Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology’s Kidney Week 2022
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick? 
    Via TheNewswire.com
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    By David Willey, Benzinga 
    Via News Direct
    Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells
    You may remember learning that mitochondria are the powerhouse of the cells, but do you know the dangers that result if these cell superheroes get sick?  
    Via Benzinga
    Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference
    Presentation to Highlight Late-Stage Program in Hyperphosphatemia and Early-Stage Program to Combat Diseases of Mitochondrial Dysfunction 
    From Unicycive Therapeutics, Inc.
    Via GlobeNewswire
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
    Via TheNewswire.com
    How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication
    Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States. 37 million American adults have CKD and more than 600,000... 
    Via Benzinga
    The Daily Biotech Pulse: Sesen Bio Stops Lead Assest Development In US, FDA Approves Eton Pharma's Partial Seizures Drug, Bavarian Nordic Inks Multiple Supply Pact For Monkeypox Vaccine
    Here's a roundup of top developments in the biotech space over the last 24 hours: 
    Via Benzinga
    CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases
    Vancouver, British Columbia--(Newsfile Corp. - June 29, 2022) - Business Television (BTV) chats with Shalabh Gupta, M.D., CEO of Unicycive... 
    Via Newsfile
    Benzinga's Top Ratings Upgrades, Downgrades For June 8, 2022
    Upgrades 
    Via Benzinga
    Traders News Source Interviews Dr. Shalabh Gupta, CEO at Unicycive Therapeutics, Inc.
    NEW YORK, NY / ACCESSWIRE / May 24, 2022 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid cap publicly traded companies recently issued a... 
    From Traders News Source
    Via AccessWire
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers 1Life Healthcare (NASDAQ:ONEM) shares moved upwards by 22.4% to $9.58 during Wednesday's after-market session. The market value of their outstanding shares is at $1.8 billion. The company's, Q1... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's After-Market Session
    Gainers 
    Via Benzinga
    12 Health Care Stocks Moving In Wednesday's After-Market Session
    Gainers Unicycive Therapeutics (NASDAQ:UNCY) shares moved upwards by 9.9% to $1.0 during Wednesday's after-market session. The company's market cap stands at $15.0 million. 
    Via Benzinga
    Glancy Prongay & Murray LLP Announces Investigation of Unicycive Therapeutics, Inc.
    From Glancy Prongay & Murray LLP
    Via Business Wire
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Gainers China SXT Pharmaceuticals (NASDAQ:SXTC) stock moved upwards by 45.0% to $0.29 during Tuesday's pre-market session. The company's market cap stands at $8.5 million. 
    Via Benzinga
    < Previous 1 2
    ...
    5 6 7 8 9 10 11 12 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.